Fingolimod 0.5mg/daily + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Demylelinating Optic Neuritis
Conditions
Acute Demylelinating Optic Neuritis
Trial Timeline
Aug 1, 2013 → May 1, 2014
NCT ID
NCT01757691About Fingolimod 0.5mg/daily + Placebo
Fingolimod 0.5mg/daily + Placebo is a phase 2 stage product being developed by Novartis for Acute Demylelinating Optic Neuritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01757691. Target conditions include Acute Demylelinating Optic Neuritis.
What happened to similar drugs?
20 of 20 similar drugs in Acute Demylelinating Optic Neuritis were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01757691 | Phase 2 | Terminated |
Competing Products
20 competing products in Acute Demylelinating Optic Neuritis